These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 12360545

  • 1. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA, Holford NH.
    Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
    [Abstract] [Full Text] [Related]

  • 2. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
    Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW.
    Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA, Morris JG, Rail D, O'Sullivan DJ, Williamson PM, Genge S, Reid WG, Broe GA.
    Med J Aust; 1987 Feb 16; 146(4):195-8. PubMed ID: 3553878
    [Abstract] [Full Text] [Related]

  • 5. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov 16; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R, Lyons K, McGuire D, Silverstein P, Zwiebel F, Robischon M, Koller WC.
    Mov Disord; 1997 Sep 16; 12(5):677-81. PubMed ID: 9380047
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Parkinson Study Group.
    Arch Neurol; 2004 Jul 16; 61(7):1044-53. PubMed ID: 15262734
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M, Riopelle R, Libman I, Bouchard S.
    Adv Neurol; 1987 Jul 16; 45():535-8. PubMed ID: 3548263
    [No Abstract] [Full Text] [Related]

  • 13. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD, Delgado MR.
    Clin Neuropharmacol; 1985 Jul 16; 8(1):73-7. PubMed ID: 3978651
    [Abstract] [Full Text] [Related]

  • 14. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.
    Nakanishi T, Mizuno Y, Goto I, Iwata M, Kanazawa I, Kowa H, Mannen T, Nishitani H, Ogawa N, Takahashi A.
    Eur Neurol; 1988 Jul 16; 28 Suppl 1():3-8. PubMed ID: 3378560
    [Abstract] [Full Text] [Related]

  • 15. New concepts in the treatment of Parkinson's disease.
    Ahlskog JE, Wilkinson JM.
    Am Fam Physician; 1990 Feb 16; 41(2):574-84. PubMed ID: 1967895
    [Abstract] [Full Text] [Related]

  • 16. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A.
    Clin Neuropharmacol; 2009 Feb 16; 32(4):189-92. PubMed ID: 19620848
    [Abstract] [Full Text] [Related]

  • 17. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA, Pfeiffer RF, Tagliati M, Kastenholz KV, DeRoche C, Slevin JT.
    Clin Ther; 2005 Jan 16; 27(1):58-63. PubMed ID: 15763606
    [Abstract] [Full Text] [Related]

  • 18. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH, Klasser M, Reichmann H.
    Fortschr Neurol Psychiatr; 2008 Oct 16; 76(10):594-9. PubMed ID: 18833504
    [Abstract] [Full Text] [Related]

  • 19. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr 16; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 20. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC, Mendoza MM, Yahr MD.
    Adv Biochem Psychopharmacol; 1980 Apr 16; 23():271-5. PubMed ID: 7395618
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.